keyword
MENU ▼
Read by QxMD icon Read
search

Cardiac Chemotherapy

keyword
https://www.readbyqxmd.com/read/29657310/cardiac-amyloidosis-myocardial-biopsy-as-a-tool-in-chemotherapy-implementation-and-scd-prevention
#1
Małgorzata Cichoń, Katarzyna Mizia-Stec, Romuald Wojnicz, Piotr Kukla, Magdalena Drożdż
No abstract text is available yet for this article.
April 15, 2018: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29650363/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-open-label-randomised-phase-3-trial
#2
Annemieke Cats, Edwin P M Jansen, Nicole C T van Grieken, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Elma Meershoek-Klein Kranenbarg, Henk Boot, Anouk K Trip, H A Maurits Swellengrebel, Hanneke W M van Laarhoven, Hein Putter, Johanna W van Sandick, Mark I van Berge Henegouwen, Henk H Hartgrink, Harm van Tinteren, Cornelis J H van de Velde, Marcel Verheij
BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies have not been investigated in a head to head comparison. We aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma. METHODS: In this investigator-initiated, open-label, randomised phase 3 trial, we enrolled patients aged 18 years or older who had stage IB- IVA resectable gastric or gastro-oesophageal adenocarcinoma (as defined by the American Joint Committee on Cancer, sixth edition), with a WHO performance status of 0 or 1, and adequate cardiac, bone marrow, liver, and kidney function...
April 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29629020/diagnosis-treatment-and-prevention-of-cardiovascular-toxicity-related-to-anti-cancer-treatment-in-clinical-practice-an-opinion-paper-from-the-working-group-on-cardio-oncology-of-the-korean-society-of-echocardiography
#3
REVIEW
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity...
March 2018: Journal of Cardiovascular Ultrasound
https://www.readbyqxmd.com/read/29620051/manipulation-free-cultures-of-human-ipsc-derived-cardiomyocytes-offer-a-novel-screening-method-for-cardiotoxicity
#4
Sheeja Rajasingh, Dona Greta Isai, Saheli Samanta, Zhi-Gang Zhou, Buddhadeb Dawn, William H Kinsey, Andras Czirok, Johnson Rajasingh
Induced pluripotent stem cell (iPSC)-based cardiac regenerative medicine requires the efficient generation, structural soundness and proper functioning of mature cardiomyocytes, derived from the patient's somatic cells. The most important functional property of cardiomyocytes is the ability to contract. Currently available methods routinely used to test and quantify cardiomyocyte function involve techniques that are labor-intensive, invasive, require sophisticated instruments or can adversely affect cell vitality...
April 5, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29617796/primary-cardiac-synovial-sarcoma-an-asymptomatic-patient-8-years-after-the-primary-surgery
#5
Wael Braham, Angelo Pisani, Bastien Poitier, Aurélie Sannier
Primary cardiac synovial sarcoma is an extremely rare disease. Its prognosis is poor with a median survival time of 24 months, even when adequate and timely treatment is given. This case reports a 61-year-old woman presenting with primary cardiac synovial sarcoma with an 8-year survival time following surgical and adjuvant chemotherapy.
March 30, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29617509/a-rare-cause-of-abdominal-pain-in-childhood-cardiac-angiosarcoma
#6
Elvan Caglar Citak, Murat Ozeren, M Kerem Karaca, Derya Karpuz, Feryal Karahan, Eda Bengi Yilmaz, Yuksel Balci, Pelin Ozcan Kara, Rabia Bozdogan Arpaci
Cardiac angiosarcomas are extremely rare in childhood, they are rapidly progressive tumours that often present themselves as diagnostic dilemmas, resulting in delayed diagnosis. Also, extracardiac manifestations, including abdominal pain, are extremely rare in patients with intracardiac tumors. We herein present the case of a 15-year-old girl who presented with abdominal pain. Echocardiography and thoracic computed tomography showed right atrial mass. The patient underwent surgery, chemotherapy, and radiotherapy...
January 2018: Brazilian Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/29616834/omitting-cardiophrenic-lymph-nodes-in-the-treatment-of-patients-with-hodgkin-lymphoma-via-modified-involved-site-radiation-therapy
#7
Chelsea C Pinnix, Andrew Wirth, Sarah A Milgrom, Therese Y Andraos, Michalis Aristophanous, Mary Pham, Donald Hancock, Ethan B Ludmir, Jillian R Gunther, Michelle A Fanale, Yasuhiro Oki, Loretta Nastoupil, Hubert H Chuang, N George Mikhaeel, Bouthaina S Dabaja
Cardiophrenic lymph nodes (CPLNs) are occasionally involved in Hodgkin lymphoma (HL). We characterized the incidence of CPLN involvement among 169 HL patients and evaluated outcomes after treatment with omission of the CPLN region from the involved-site radiation therapy (ISRT) field. Three types of RT fields were used: standard (S)-ISRT, reduced-dose (RD)-ISRT (lower dose to CPLNs, standard to other sites), or modified (M)-ISRT (omission of CPLNs). CPLNs were involved at diagnosis in 29 patients (17%). Of the 20 patients who received RT after complete response to chemotherapy, 4(20%) received S-ISRT, 8(40%) RD-ISRT, and 8(40%) M-ISRT...
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29615371/intraluminal-brachytherapy-boost-following-external-beam-radiotherapy-with-concurrent-chemotherapy-of-oesophagus-carcinoma-results-of-a-prospective-observational-study
#8
P Nag, O P Gurjar, V Bhandari, K L Gupta, P Bagdare, H Goyal
PURPOSE: The main objective of our study is to evaluate response and toxicity profile in patients receiving external beam radiotherapy with concurrent chemotherapy followed by intraluminal brachytherapy boost for a carcinoma of the oesophagus. MATERIAL AND METHODS: Twenty patients with biopsy-proven carcinoma of the oesophagus received external beam radiotherapy (50Gy in 25 fractions) with concurrent chemotherapy (cisplatin: 40mg/m2 ). After a gap of two to three weeks, intraluminal brachytherapy (10Gy in two fractions each 1 week apart by a high dose rate60 Co source) was given...
March 31, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29608498/cardioprotection-in-the-modern-era-of-cancer-chemotherapy
#9
Anuradha Godishala, Shu Yang, Aarti Asnani
The current arsenal of cancer chemotherapy is broad and rapidly expanding and includes conventional cytotoxic agents and targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death...
May 2018: Cardiology in Review
https://www.readbyqxmd.com/read/29603386/natural-history-of-myocardial-deformation-in-children-adolescents-and-young-adults-exposed-to-anthracyclines-systematic-review-and-meta-analysis
#10
Mirela Tuzovic, Pei-Tzu Wu, Samuel Kianmahd, Kim-Lien Nguyen
OBJECTIVE: Anthracyclines are widely used to treat solid and hematologic malignancies, but are known to cause cardiotoxicity. As more childhood cancer survivors reach adulthood due to improvements in oncologic treatments, they become susceptible to late and progressive anthracycline-induced cardiotoxicity. Nonetheless, diagnostic criteria for early detection of cardiac dysfunction are not well defined in children, adolescent, and young adults (CAYA, ages 1-40 years). We present a natural history of the changes in myocardial deformation in CAYA patients after anthracycline therapy...
March 30, 2018: Echocardiography
https://www.readbyqxmd.com/read/29600103/report-of-a-lung-carcinoma-extended-to-the-left-atrium-through-pulmonary-vein
#11
Federico Cipriano, Lycio U Dessoti, Alfredo José Rodrigues, Walter Vilella de Andrade Vicente, Fernando Chahud, Paulo Roberto B Evora
Lung cancers may extend along or grow through the pulmonary veins to invade or lie within the left atrium (LA). A 62-year-old man, previously healthy, presented with 1-month ventilatory-independent right hemithorax back pain, dry cough and large effort dyspnea. He also referred weight loss of 12 kg in 10 months and denied hemoptysis. As antecedents, he smoked for 40 years and moderate daily alcoholism. On physical examination, the patient was in good general condition, hydrated and regular respiration at rest [blood pressure (BP) =120/80 mmHg; heart rate (HR) =90 bpm; respiratory rate (RR) =16 rpm]...
January 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29599341/radiotherapy-induced-early-ecg-changes-and-their-comparison-with-echocardiography-in-patients-with-early-stage-breast-cancer
#12
Suvi Sirkku Tuohinen, Konsta Keski-Pukkila, Tanja Skyttä, Heini Huhtala, Vesa Virtanen, Pirkko-Liisa Kellokumpu-Lehtinen, Pekka Raatikainen, Kjell Nikus
BACKGROUND: Early electrocardiogram (ECG) changes after breast cancer radiotherapy (RT) have been reported, but their characteristics and associated factors are largely unknown. This study aimed to explore early RT-induced ECG changes and to compare them with echocardiography changes. MATERIALS AND METHODS: Sixty eligible patients with chemotherapy-naïve left-sided and 20 with right-sided breast cancer were evaluated with echocardiography, blood samples and ECG before and after RT...
April 2018: Anticancer Research
https://www.readbyqxmd.com/read/29594044/a-phase-ib-ii-study-of-ganetespib-with-doxorubicin-in-advanced-solid-tumors-including-relapsed-refractory-small-cell-lung-cancer
#13
Deepa S Subramaniam, Stephen V Liu, Jeanette Crawford, Jenna Kramer, Jillian Thompson, Hongkun Wang, Giuseppe Giaccone
Introduction: Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and is characterized by high response rates to cytotoxic chemotherapy and equally high rates of relapse. Many resistance mechanisms have been proposed including resistance to doxorubicin via induction of a heat shock response. Ganetespib is a novel and potent non-geldanamycin heat shock protein 90 (Hsp90) inhibitor. In preclinical studies, synergy between ganetespib and doxorubicin was shown. We conducted a phase Ib/II study of the safety, tolerability, and preliminary efficacy of the combination of ganetespib and doxorubicin...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29593308/the-anti-cancer-multikinase-inhibitor-sorafenib-impairs-cardiac-contractility-by-reducing-phospholamban-phosphorylation-and-sarcoplasmic-calcium-transients
#14
Christopher Schneider, Markus Wallner, Ewald Kolesnik, Viktoria Herbst, Heinrich Mächler, Martin Pichler, Dirk von Lewinski, Simon Sedej, Peter P Rainer
Tyrosine-kinase inhibitors (TKIs) have revolutionized cancer therapy in recent years. Although more targeted than conventional chemotherapy, TKIs exhibit substantial cardiotoxicity, often manifesting as hypertension or heart failure. Here, we assessed myocyte intrinsic cardiotoxic effects of the TKI sorafenib and investigated underlying alterations of myocyte calcium homeostasis. We found that sorafenib reversibly decreased developed force in auxotonically contracting human myocardia (3 µM: -25 ± 4%, 10 µM: -29 ± 7%, 30 µM: -43 ± 12%, p < 0...
March 28, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29582557/five-year-results-of-a-phase-ii-trial-of-preoperative-5-fluorouracil-epirubicin-cyclophosphamide-followed-by-docetaxel-with-capecitabine-wtx-with-trastuzumab-in-her2-positive-patients-for-patients-with-stage-ii-or-iii-breast-cancer
#15
Frankie Ann Holmes, Beth A Hellerstedt, John E Pippen, Svetislava J Vukelja, Rufus P Collea, Darren M Kocs, Joanne L Blum, Kristi J McIntyre, Minal A Barve, Barry D Brooks, Cynthia R Osborne, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy
We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5-fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2-positive disease) and to evaluate 5-year disease-free survival (DFS) associated with this preoperative regimen. Chemotherapy included four cycles of FEC100 (5-fluorouracil 500 mg/m2 , epirubicin 100 mg/m2 , cyclophosphamide 500 mg/m2 IV on Day 1 every 21 days) followed by 4 21-day cycles of docetaxel (35 mg/m2  days 1 and 8) concurrently with capecitabine (825 mg/m2 orally twice daily for 14 days followed by 7 days off) (wTX)...
March 26, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29581480/late-cardiovascular-morbidity-and-mortality-following-pediatric-allogeneic-hematopoietic-cell-transplantation
#16
Christine N Duncan, Ruta Brazauskas, Jiaxing Huang, Bronwen E Shaw, Navneet S Majhail, Bipin N Savani, Mary E D Flowers, Minoo Battiwalla, Kristen Beebe, Andrew C Dietz, Christopher C Dvorak, Roger Giller, David A Jacobsohn, Morris Kletzel, Paul L Martin, Eneida R Nemecek, Brandon Nuechterlein, Julie-An Talano, Michael A Pulsipher, K Scott Baker
We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and potential risk factors. The median duration of follow-up was 97 months (range 24-230). 4.2% of survivors experienced at least one of the primary outcomes including coronary artery disease (0.2%), cerebrovascular accident (0...
March 26, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29576422/late-characterisation-of-cardiac-effects-following-anthracycline-and-trastuzumab-treatment-in-breast-cancer-patients
#17
Ashlee Kimball, Sanjana Patil, Bogda Koczwara, Karthigesh Sree Raman, Rebecca Perry, Suchi Grover, Joseph Selvanayagam
BACKGROUND: Anthracycline (A) and trastuzumab (T) chemotherapy have well-recognized cardiac toxicity, potentially leading to significant morbidity and mortality. Our previous work in 46 prospectively enrolled breast cancer patients showed early left ventricular (LV) and right ventricular (RV) function decline at 1 and 3 months, but only persistent RV dysfunction at 12 months which correlated with myocardial oedema observed early (1 and 3 months) after administration of chemotherapy regimes...
March 8, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29567630/anthracycline-induced-cardiotoxicity-a-multicenter-randomised-trial-comparing-two-strategies-for-guiding-prevention-with-enalapril-the-international-cardiooncology-society-one-trial
#18
Daniela Cardinale, Fabio Ciceri, Roberto Latini, Maria Grazia Franzosi, Maria Teresa Sandri, Maurizio Civelli, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Raffaele Cavina, Enrico Barbieri, Stefania Gori, Alessandro Colombo, Giuseppe Curigliano, Michela Salvatici, Antonio Rizzo, Francesco Ghisoni, Alessandra Bianchi, Cristina Falci, Michele Aquilina, Andrea Rocca, Anna Monopoli, Carlo Milandri, Giuseppe Rossetti, Marco Bregni, Marco Sicuro, Alessandra Malossi, Daniele Nassiacos, Claudio Verusio, Monica Giordano, Lidia Staszewsky, Simona Barlera, Enrico B Nicolis, Michela Magnoli, Serge Masson, Carlo M Cipolla
BACKGROUND: Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS: The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-label trial conducted in 21 Italian hospitals. Patients were randomly assigned to two strategies: enalapril in all patients started before chemotherapy (CT; 'prevention' arm), and enalapril started only in patients with an increase in troponin during or after CT ('troponin-triggered' arm)...
May 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29566148/co-administration-of-resveratrol-with-doxorubicin-in-young-mice-attenuates-detrimental-late-occurring-cardiovascular-changes
#19
Nobutoshi Matsumura, Beshay N Zordoky, Ian M Robertson, Shereen M Hamza, Nirmal Parajuli, Carrie-Lynn M Soltys, Donna L Beker, Marianne K Grant, Maria Razzoli, Alessandro Bartolomucci, Jason R B Dyck
AIMS: Doxorubicin (DOX) is among the most effective chemotherapies used in pediatric cancer patients. However, the clinical utility of DOX is offset by its well-known cardiotoxicity, which often does not appear until later in life. Since hypertension significantly increases the risk of late-onset heart failure in childhood cancer survivors, we investigated whether juvenile DOX exposure impairs the ability to adapt to angiotensin II (Ang II)-induced hypertension later in life as well as treatments that could prevent this...
March 16, 2018: Cardiovascular Research
https://www.readbyqxmd.com/read/29565554/a-complementary-chemical-and-genomic-screening-approach-for-druggable-targets-in-the-nrf2-pathway-and-small-molecule-inhibitors-to-overcome-cancer-cell-drug-resistance
#20
James H Matthews, Xiao Liang, Valerie J Paul, Hendrik Luesch
Resistance to chemotherapy is a major obstacle in the treatment of a wide array of different types of cancer. Chemotherapeutic drug resistance is achieved by cancer cells by a variety of different mechanisms, which can be either compound specific or general. An emerging mechanism for nonspecific chemotherapeutic drug resistance relies on hyperactivity of the transcription factor Nrf2. Normally Nrf2 levels are tightly regulated by the ubiquitin-proteasome system; however, mutations in genes responsible for this regulation are common in many cancer types, resulting in increased expression of Nrf2, activation of its downstream target genes, and resistance to a variety of chemotherapeutic agents...
March 22, 2018: ACS Chemical Biology
keyword
keyword
106610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"